Caporali R, Ravasio R, Raimondo P, Salaffi F. Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy. Grhta [Internet]. 2021 Jul. 12 [cited 2024 Nov. 23];8(1):69-7. Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/2267